Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-A12 plus Sorafenib in Advanced HCC
NCT00906373Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2009
- Primary completion
- Oct 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cixutumumab in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by Eli Lilly and Company. Primary endpoint: Progression Free Survival up to 12 months. Started May 2009; status: completed.
02
Drugs
cixutumumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00906373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00906373.